Compare SEVN & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEVN | PYXS |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.0M | 141.3M |
| IPO Year | 2008 | 2021 |
| Metric | SEVN | PYXS |
|---|---|---|
| Price | $7.41 | $3.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $10.50 | $7.00 |
| AVG Volume (30 Days) | 114.4K | ★ 933.1K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | ★ 13.90% | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $29,383,000.00 | $13,858,000.00 |
| Revenue This Year | $27.75 | N/A |
| Revenue Next Year | $4.06 | $7,043.98 |
| P/E Ratio | $38.79 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.37 | $1.03 |
| 52 Week High | $11.15 | $5.55 |
| Indicator | SEVN | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 34.32 | 49.54 |
| Support Level | N/A | $1.37 |
| Resistance Level | $7.84 | $3.45 |
| Average True Range (ATR) | 0.12 | 0.33 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 9.82 | 31.32 |
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.